Secondary organizing pneumonia (bronchiolitis obliterans with organizing pneumonia) associated with adalimumab for treatment of chronic plaque psoriasis by Doolan, Brent J et al.
UC Davis
Dermatology Online Journal
Title
Secondary organizing pneumonia (bronchiolitis obliterans with organizing pneumonia) 
associated with adalimumab for treatment of chronic plaque psoriasis
Permalink
https://escholarship.org/uc/item/7m04d30q
Journal
Dermatology Online Journal, 25(10)
Authors
Doolan, Brent J
Cranwell, William C
Nicolopoulos, Jenny
et al.
Publication Date
2019
License
CC BY-NC-ND 4.0
eScholarship.org Powered by the California Digital Library
University of California
Volume 25 Number 10| October 2019| 
25(10):18 
 
 
- 1 - 
Dermatology Online Journal  ||  Letter 
Secondary organizing pneumonia (bronchiolitis obliterans 
with organizing pneumonia) associated with adalimumab 
for treatment of chronic plaque psoriasis 
 
Brent J Doolan, BSc MBBS MPH&TM, William C Cranwell MBBS(Hons) BMedSc(Hons) MPH&TM, Jenny 
Nicolopoulos, MBBS FACD, Con Dolianitis, BA MBBS Mmed FACD 
Affiliations: Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia 
Corresponding Author: Brent J Doolan, The Royal Melbourne Hospital, Melbourne, Victoria, Australia 3050, Tel: 61-3 9342 4531, Email: 
brentjamesdoolan@gmail.com 
 
 
Keywords: secondary organizing pneumonia, adalimumab, 
biologics, psoriasis, bronchiolitis obliterans with organizing 
pneumonia 
 
Introduction 
Organizing pneumonia (formerly bronchiolitis 
obliterans with organizing pneumonia) is defined 
histopathologically by intra-alveolar buds of 
granulation tissue, consisting of intermixed 
myofibroblasts and connective tissue [1]. The 
pathological pattern of organizing pneumonia may 
be idiopathic (cryptogenic organizing pneumonia) 
or due to a determined cause (secondary organizing 
pneumonia), including connective tissue disorders, 
infectious diseases, parasitic infection, organ 
transplantation and drugs [2]. Drugs used commonly 
in dermatology implicated in the pathogenesis of 
secondary organizing pneumonia include sirolimus, 
minocycline, rituximab, tacrolimus, thalidomide, and 
methotrexate [2]. If left untreated, organizing 
pneumonia can progress to pulmonary fibrosis, with 
a mortality rate between 5-27% [2]. We report a case 
of drug-induced secondary organizing pneumonia 
in a patient on the tumor necrosis factor inhibitor, 
adalimumab, for chronic plaque psoriasis. 
 
Case Synopsis 
We report a 68-year-old woman with a longstanding 
history of chronic plaque psoriasis. Medical history 
was significant for aortic incompetence, 
hypercholesterolaemia, paroxysmal atrial fibrillation, 
and hypertension. Regular medications included 
atorvastatin, atenolol, and apixaban. She was 
commenced on adalimumab 40mg subcutaneous 
every two weeks and after four months of treatment 
had a significant reduction in her psoriasis (Psoriasis 
Area Severity Index score decrease from 17.1 to 1.2). 
After 8 years of treatment she complained of a 
gradual-onset, non-productive cough with 
associated generalized fatigue and mild dyspnea. 
A computed tomography (CT) scan was performed 
to investigate abdominal discomfort and this 
incidentally revealed consolidation with linear inter- 
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and intra-lobular septal thickening in the right lower 
lobe. A dedicated high resolution high resolution CT 
(HRCT) demonstrated ground-glass opacities in the 
left lower lobe with ongoing thickening of the 
interlobular septa bi-basally, along with a 2.5mm 
sub-pleural nodule. There was preserved lung 
architecture and no pathological lymphadenopathy. 
All blood tests including full blood examination, 
inflammatory markers, antinuclear antibodies, and 
QuantiFERON-TB Gold were all within normal range. 
Bronchoscopy revealed a fibroinflammatory process 
consistent with organizing pneumonia, without 
necrosis or vasculitis. Bronchoalveolar lavage yielded 
a lymphocytosis of 85% of returned cells, excluding 
infection, with no cytological evidence of 
malignancy. She was diagnosed with organizing 
pneumonia secondary to adalimumab and biologic 
treatment was discontinued. She was commenced 
on prednisolone 50mg daily, which was tapered over 
6 weeks. Repeat HRCT at 9 weeks revealed significant 
improvement in pulmonary pathology and 
resolution of her symptoms. 
 
Case Discussion 
Tumor necrosis factor is a cytokine that has been 
implicated as both a pro- and anti-fibrotic agent 
involved in the pathophysiology of pulmonary 
fibrosis [3]. Tumor necrosis factor has been shown to 
promote pulmonary tissue repair, eliminating 
inflammatory cells by inducing apoptosis and 
preventing the development of fibrosis [3]. It has also 
been shown to play a pro-fibrotic role by 
upregulating messenger pathways that activate 
extracellular regulated kinase-specific pathways in 
fibroblasts [4]. Specifically, by upregulating the 
expression of transforming growth factor β1 in the 
lungs, TNF increase in the expression and DNA 
binding of the activator protein-1, and regulation of 
p21, a cyclin-dependent kinase inhibitor that plays a 
key role in regulating cell cycle progression and 
apoptosis [4]. Therefore, TNF inhibitors including 
adalimumab have been postulated as a potential 
therapeutic pathway for interstitial lung disease [5]. 
However, there are an increasing number of cases of 
drug-induced lung disease by these agents [5], 
especially in those that have factors associated with 
increased risk of interstitial lung disease, such as 
smoking, autoimmune disease, and concomitant 
therapies such as methotrexate, azathioprine, and 
cyclophosphamide [4]. Thus, a careful clinical 
evaluation including assessment of previous 
pulmonary disease, respiratory radiological findings, 
and risk factors for interstitial lung disease should be 
undertaken when considering biologic therapy. 
 
Conclusion 
Given the increasing incidence of biologic treatment 
in the management of dermatological conditions, 
clinicians should be aware of secondary organizing 
pneumonia as a possible side effect of TNF inhibitor 
therapy. 
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